Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin and Venetoclax with Obinutuzumab or Rituximab in R/R FL and DLBCL
NCT03135262Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of idasanutlin in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Roche. Primary endpoints: Recommended Phase II Dose of Idasanutlin, Recommended Phase II Dose of Venetoclax and 3 more. Started Jun 2017; status: terminated.
02
Drugs
idasanutlin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03135262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135262.